Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALIMNASDAQ:LXRXNASDAQ:RGLSNASDAQ:XOMA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALIMAlimera Sciences$5.54$5.55$2.61▼$5.65$290.24M1.25376,318 shsN/ALXRXLexicon Pharmaceuticals$0.72-0.9%$0.49$0.28▼$2.45$178.40M1.026.49 million shs4.08 million shsRGLSRegulus Therapeutics$7.85-1.6%$1.84$0.83▼$8.20$520.01M1.03858,625 shs5.67 million shsXOMAXOMA$23.44-2.5%$21.27$18.35▼$35.00$280.18M128,056 shs31,698 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALIMAlimera Sciences0.00%0.00%0.00%0.00%+50.54%LXRXLexicon Pharmaceuticals+9.27%+8.78%+58.59%-10.81%-52.55%RGLSRegulus Therapeutics+136.80%+212.94%+356.00%+698.00%+246.96%XOMAXOMA-1.39%+3.00%+20.62%-8.45%-5.13%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALIMAlimera SciencesN/AN/AN/AN/AN/AN/AN/AN/ALXRXLexicon Pharmaceuticals3.5259 of 5 stars4.24.00.00.03.21.70.6RGLSRegulus Therapeutics1.6463 of 5 stars2.25.00.00.02.41.70.0XOMAXOMA4.0329 of 5 stars3.52.00.03.02.73.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALIMAlimera Sciences 2.00Hold$6.008.30% UpsideLXRXLexicon Pharmaceuticals 2.40Hold$3.67406.10% UpsideRGLSRegulus Therapeutics 2.33Hold$8.508.28% UpsideXOMAXOMA 3.00Buy$69.50196.50% UpsideCurrent Analyst Ratings BreakdownLatest RGLS, ALIM, LXRX, and XOMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/1/2025RGLSRegulus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$9.004/30/2025RGLSRegulus TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$7.004/30/2025RGLSRegulus TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$28.00 ➝ $11.004/30/2025RGLSRegulus TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$8.00 ➝ $7.004/17/2025XOMAXOMABenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$35.003/28/2025LXRXLexicon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.003/28/2025XOMAXOMAHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$104.00 ➝ $104.003/27/2025RGLSRegulus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$3.00 ➝ $6.003/19/2025XOMAXOMAHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$104.00 ➝ $104.003/17/2025RGLSRegulus TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.003/14/2025RGLSRegulus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALIMAlimera Sciences$99.68M2.91N/AN/A$0.88 per share6.30LXRXLexicon Pharmaceuticals$31.08M5.74N/AN/A$0.38 per share1.91RGLSRegulus TherapeuticsN/AN/AN/AN/A$1.05 per shareN/AXOMAXOMA$10.22M27.41N/AN/A$7.72 per share3.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALIMAlimera Sciences-$20.13M-$1.57N/A26.38N/A-14.74%-33.70%-9.63%N/ALXRXLexicon Pharmaceuticals-$177.12M-$0.64N/AN/AN/A-4,109.41%-107.38%-64.09%5/1/2025 (Estimated)RGLSRegulus Therapeutics-$30.04M-$0.87N/AN/AN/AN/A-53.07%-48.58%5/8/2025 (Estimated)XOMAXOMA-$40.83M-$2.07N/AN/AN/A-151.34%-24.95%-9.64%5/8/2025 (Estimated)Latest RGLS, ALIM, LXRX, and XOMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025RGLSRegulus Therapeutics-$0.33N/AN/AN/AN/AN/A5/8/2025Q1 2025XOMAXOMA-$0.26N/AN/AN/A$6.75 millionN/A5/1/2025Q1 2025LXRXLexicon Pharmaceuticals-$0.10N/AN/AN/A$1.26 millionN/A3/20/2025Q4 2024RGLSRegulus Therapeutics-$0.20-$0.20N/A-$0.20N/AN/A3/17/2025Q4 2024XOMAXOMA-$0.29-$0.46-$0.17-$0.46$8.75 million$8.70 million3/6/2025Q4 2024LXRXLexicon Pharmaceuticals-$0.11-$0.09+$0.02-$0.09$6.48 million$26.55 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALIMAlimera SciencesN/AN/AN/AN/AN/ALXRXLexicon PharmaceuticalsN/AN/AN/AN/AN/ARGLSRegulus TherapeuticsN/AN/AN/AN/AN/AXOMAXOMAN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALIMAlimera Sciences1.802.792.62LXRXLexicon Pharmaceuticals0.567.457.43RGLSRegulus TherapeuticsN/A14.1514.14XOMAXOMA1.287.527.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALIMAlimera Sciences99.83%LXRXLexicon Pharmaceuticals74.70%RGLSRegulus Therapeutics92.38%XOMAXOMA95.92%Insider OwnershipCompanyInsider OwnershipALIMAlimera Sciences31.40%LXRXLexicon Pharmaceuticals6.80%RGLSRegulus Therapeutics4.35%XOMAXOMA7.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALIMAlimera Sciences15052.39 million35.94 millionOptionableLXRXLexicon Pharmaceuticals140246.24 million229.49 millionOptionableRGLSRegulus Therapeutics3066.24 million62.65 millionOptionableXOMAXOMA1011.95 million10.94 millionOptionableRGLS, ALIM, LXRX, and XOMA HeadlinesRecent News About These CompaniesHigh Growth Tech Stocks In The US To Watch April 2025April 22, 2025 | uk.finance.yahoo.comXOMA (NASDAQ:XOMA) Now Covered by BenchmarkApril 19, 2025 | marketbeat.comBenchmark Initiates Coverage of XOMA Royalty Corporation - Preferred Stock (XOMAP) with Buy RecommendationApril 18, 2025 | msn.comXoma initiated with a Buy at BenchmarkApril 17, 2025 | markets.businessinsider.comXoma (XOMA) Receives Buy Rating from Benchmark with Promising Growth Forecast | XOMA Stock NewsApril 17, 2025 | gurufocus.comXOMA Royalty Completes Sale of Kinnate Pipeline AssetsApril 14, 2025 | gurufocus.comXOMA (XOMA) Sells Kinnate Biopharma Pipeline Assets for Potential $270M | XOMA Stock NewsApril 14, 2025 | gurufocus.comXOMA Royalty Completes Sale of Kinnate Pipeline Assets | XOMA Stock NewsApril 14, 2025 | gurufocus.comXOMA Royalty Completes Sale of Kinnate Pipeline AssetsApril 14, 2025 | globenewswire.comXOMA (NASDAQ:XOMA) Stock Rating Upgraded by StockNews.comApril 13, 2025 | marketbeat.comInsider Buying: XOMA Co. (NASDAQ:XOMA) CIO Purchases 2,000 Shares of StockApril 10, 2025 | insidertrades.comXOMA Royalty Corporation (XOMA): Among Stocks Insiders Bought in April After Trump’s Tariff RolloutApril 9, 2025 | msn.comJoseph M. Limber Buys 5,243 Shares of XOMA Co. (NASDAQ:XOMA) StockApril 9, 2025 | insidertrades.comInsider Buying: XOMA Co. (NASDAQ:XOMA) Director Acquires 5,243 Shares of StockApril 9, 2025 | marketbeat.comXOMA Co. (NASDAQ:XOMA) Director Joseph M. Limber Buys 17,935 SharesApril 9, 2025 | marketbeat.comBioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3April 8, 2025 | accessnewswire.comXOMA Royalty Corporation's Preferreds Still Offer Attractive Yields With A Biotech TwistApril 8, 2025 | seekingalpha.comXOMA (NASDAQ:XOMA) Rating Lowered to "Sell" at StockNews.comApril 5, 2025 | marketbeat.comXOMA Royalty to Present at Jones Healthcare and Technology Innovation ConferenceApril 2, 2025 | globenewswire.comBradley Sitko Acquires 4,134 Shares of XOMA Co. (NASDAQ:XOMA) StockMarch 26, 2025 | insidertrades.comInsider Purchase: Chief Investment Officer of $XOMA Buys 2,800 SharesMarch 25, 2025 | quiverquant.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRGLS, ALIM, LXRX, and XOMA Company DescriptionsAlimera Sciences NASDAQ:ALIMAlimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.Lexicon Pharmaceuticals NASDAQ:LXRX$0.72 -0.01 (-0.86%) Closing price 04:00 PM EasternExtended Trading$0.72 -0.01 (-0.76%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.Regulus Therapeutics NASDAQ:RGLS$7.85 -0.13 (-1.63%) Closing price 04:00 PM EasternExtended Trading$7.87 +0.02 (+0.25%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.XOMA NASDAQ:XOMA$23.44 -0.60 (-2.50%) Closing price 04:00 PM EasternExtended Trading$23.54 +0.09 (+0.41%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Crushes Earnings, What’s Next for MSFT Stock? McDonald’s Insiders Sell Shares! Investors Should Do the Opposite Qualcomm's Earnings: 2 Reasons to Buy, 1 to Stay Away Broadcom: Buy, Hold, Sell? AI & Acquistions Paint Strong Picture Hershey Hits the Sweet Spot for Defensive Investors A Bull Case for Adobe Stock Remains Today AMD Stock Signals Strong Buy Ahead of Earnings BigBear.ai: A Short-Squeeze Is Possible, a Sharp Drop Is Likely Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
